JCC: Journal of Crohn’s and Colitis

Vita-Salute San Raffaele University
IRCCS San Raffaele Hospital
Milan, Italy

With the publication of the 2024 Impact Factor of 8.7 we now see that the Journal is increasing its impact because our articles are being cited even more frequently than before. With its 2023 Impact Factor, the Journal of Crohn’s and Colitis (JCC) is one of the top journals in the gastroenterology and hepatology field. Discover which recently published articles have been making an impact by clicking here. JCC continually strives to support the IBD Community through publication of the best original research, ECCO Guidelines and other articles. JCC is appreciated as a top venue by authors in which to publish their work.
The increasing impact of the Journal of Crohn's and Colitis is due to the ongoing support of authors and readers, but also reflects the significant advances being made at the moment in most aspects of IBD research and treatment. Let us hope that the increased Impact Factor of our Journal is paralleled by even better outcomes for patients suffering from IBD all over the world in the near future.
The JCC Editor-in-Chief, Silvio Danese, and the entire Editorial Team thank all ECCO Members, JCC authors, reviewers and readers for their support of JCC.
General Information
The Journal of Crohn's and Colitis is the official journal of the European Crohn's and Colitis Organisation (ECCO) and is concerned with the dissemination of knowledge on clinical, basic science and innovative methods related to Inflammatory Bowel Diseases (IBD).
The journal publishes Original articles, Review articles, Editorials, ECCO Papers, Viewpoints, Short reports, Abstracts and Letters to the Editor. JCC is being published every month (12 issues per year) and covers the knowledge and science related to Inflammatory Bowel Diseases: The aims are to update, innovate and challenge.
JCC is defined as an “International Journal”. Although it is the official journal of ECCO, it is open to everyone in the world interested and working in Inflammatory Bowel Diseases.
In 2010, JCC was accepted for MedLine citation, which motivates us – as ECCO – even more to work on the quality and exposure of our journal.
Note
As of 2013 Regular / Y-ECCO Membership includes online access only to the Journal of Crohn’s and Colitis (JCC) for the year of membership.
Advertising and Corporate Services
Advertising, reprints, peer-reviewed supplements are services available via our publisher Oxford University Press (OUP).
JCC Plus:
Journal of Crohn’s and Colitis Plus

Hvidovre University Hospital,
Hvidovre, Denmark

JCC Plus is an Open Access journal that will offer a broader view on IBD and its multidisciplinary care, aiming to increase the scope of published research in the field of IBD, as well as the community of readers. Rather than aiming purely for the highest Impact Factor, JCC Plus aims to reach a large number of people to create a community where experiences are shared and ideas exchanged.
In this context, the journal will favour interactions between clinicians, researchers, and patient associations, putting energy into organising and feeding forums and exchanges. The format of some publications should favour the understanding of the concepts by a broad community of readers, including patients. This would imply the broad use of graphical abstracts, and schematic representations.
Open Access
- JCC Plus will be an Open Access journal
Larger Scope
- JCC Plus will offer a broader view on IBD
- Increase the scope of published research in the field of IBD
- Increase the community of readers
- Reach a large number of readers and create a community of people exchanging experiences and brainstorming IBD topics
Global IBD
- Epidemiological and clinical studies from around the world highlighting evolving epidemiology, different clinical presentation, different priorities in disease management based on geographic location, different health systems, and more.
Systemic Manifestations of IBD and IBD Among other IMIDS
- Epidemiological and clinical studies from around the world highlighting evolving epidemiology, different clinical presentation, different priorities in disease management based on geographic location, different health systems, and more
- Broadening the IBD research community to include other healthcare providers and patients.
IBD in the society
- Giving the word to patients and patient-associations
- Publishing studies on the impact of IBD on the health care system and society
Wider view of translational and clinical IBD
- Publication of clinical trial protocols and original methods of research as well as new concepts and innovative views on disease mechanisms and management.
Strong collaborative spirit
- JCC Plus will favour interactions between clinicians, researchers, nurses, patients, and more
- Putting energy in organising and feeding forums and exchanges
- The format of some publications will be dedicated to the understanding of concepts by a broader community of readers, including patients, by bringing attention to graphical abstracts, schematic representations and more
JCC on X
Follow JCC on X to stay in the loop on newly accepted manuscripts and the dissemination of knowledge on clinical, basic science and innovative methods related to IBD!

In line with global REACH of ECCO, we aim to contribute to Rapid diagnosis and treatment by updating you on the most recent findings in IBD management. By embarking on this social platform, we strive for Equitable access to IBD research and Attain sustainable IBD care by highlighting recently accepted manuscripts impacting your daily clinical practice. JCC also welcomes basic and translational manuscripts, offering our global readership insights in recent advances in Causes of IBD. Finally, our social platform is there to advertise manuscripts on all aspects of IBD care, ensuring a Holistic approach for IBD care.
Authors submitting to JCC are encouraged to include a graphical abstract with their revised manuscripts for enhanced visibility. Join us as we share groundbreaking research with a wider, international audience on social media! Let’s REACH together …